EMA Authorised: Hetronifly (serplulimab) — Accord Healthcare S.L.U.

View source ↗

Summary

EMA authorised Hetronifly (serplulimab) for small cell lung cancer, with Accord Healthcare S.L.U. as the marketing authorisation holder. The product is designat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Hetronifly (serplulimab)

Snippet

Status: Authorised. Therapeutic area: Small Cell Lung Carcinoma. MAH: Accord Healthcare S.L.U.. Decision date: 04/12/2025. Orphan medicine